Company intelligence / Profile preview

Xilio Development

Waltham, Massachusetts, United States

Ownership: Public · XLO
Employees: ~70
Development stage: Other

Overview

Xilio Therapeutics has reported early-phase clinical results for its lead candidates, including vilastobart (masked anti-CTLA-4 + PD-L1) in combination with atezolizumab and efarindodekin alfa (masked IL-12), demonstrating tumor-selective activation with the aim to improve efficacy and minimize systemic toxicity in various advanced solid tumors and colorectal cancer. Several other programs are in preclinical and IND-enabling stages.

Therapeutic areas: Oncology
Modalities: AntibodyBispecific monoclonal antibodyCytokineProtein
Industry: Biotech

Partnerships

AbbVie (collaboration and option agreement for tumor-activated immunotherapies as of February 2025)

Beyond the preview

Go deeper on Xilio Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xilio Development.

Explore the full profile